We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Glycosylation Gives Growth Advantage to Hypoxic Tumor Cells

By LabMedica International staff writers
Posted on 02 Sep 2012
Tumors survive in a microenvironment characterized by low oxygen levels (hypoxia) by shifting the metabolism of their cells away from the glycolytic pathway used by normal cells and onto the alternative pentose phosphate pathway.

The pentose phosphate pathway (also called the phosphogluconate pathway and the hexose monophosphate shunt) is a process that generates NADPH and pentoses (five-carbon sugars). More...
There are two distinct phases in the pathway. The first is the oxidative phase, in which NADPH is generated, and the second is the nonoxidative synthesis of five-carbon sugars. This pathway is an alternative to glycolysis. While it does involve oxidation of glucose, its primary role is anabolic rather than catabolic. For most organisms, it takes place in the cytosol.

Investigators at the California Institute of Technology (Pasadena, USA; www.caltech.edu) studied the role of the regulatory enzyme phosphofructokinase 1 (PFK1) in the transition of cancer cells from the glycolytic pathway to the pentose phosphate pathway.

PFK1 is the most important control site in the mammalian glycolytic pathway. This step is subject to extensive regulation since it is the committed step - the first irreversible reaction unique to the glycolytic pathway. This leads to a precise control of glucose, galactose, and fructose going down the glycolytic pathway. Before this enzyme's reaction, glucose-6-phosphate can potentially travel down the pentose phosphate pathway, or be converted to glucose-1-phosphate for glycogenesis.

The investigators reported in the August 24, 2012, issue of the journal Science that the action of PFK1 was modified under hypoxic conditions by O-GlcNAcylation of the protein's amino acid serine located at position 529. This posttranslational addition of a sugar residue was orchestrated by O-linked beta-N-acetylglucosamine (O-GlcNAc).

Glycosylation inhibited PFK1 activity and redirected glucose flux through the pentose phosphate pathway, thereby conferring a selective growth advantage on cancer cells. Blocking glycosylation of PFK1 at serine 529 reduced cancer cell proliferation in vitro and impaired tumor formation in vivo.

"We have identified a novel molecular mechanism that cancer cells have coopted in order to produce intermediates that allow them to grow more rapidly and to help them combat oxidative stress," said senior author Dr. Linda Hsieh-Wilson, professor of chemistry at the California Institute of Technology. "What is unique here is that the addition of GlcNAc is dynamic and reversible. This allows a cancer cell to more rapidly alter its metabolism depending on the environment that it encounters."

Related Links:
California Institute of Technology


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
HPV Test
Allplex HPV28 Detection
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.